Market Research Report Pipeline Review of Protein Kinase C Epsilon Type | Page 3
Mechanism Of Action 29
R&D Progress 29
Small Molecule to Activate PKC Epsilon for Neurology - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
VMD-1201 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
VMD-2202 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Dormant Projects 34
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Discontinued Products 35
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Featured News & Press
Releases 36
Aug 15, 2016: Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its
Phase 2b Clinical Trial of its Lead 36
Jun 21, 2016: Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the
Synaptic Anchoring Protein PSD-95 at Neuronal Membranes 36
Jun 13, 2016: Neurotrope's Chief Scientific Officer Dr. Daniel Alkon Presents at the Gordon Conference:
Drugs That Target Common Mechanisms for Synaptic Restoration in Mental Retardation and Alzheimer's
Disease 37
Mar 08, 2016: Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC
epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model 38
Feb 11, 2016: Neurotrope Doses First Patients in Phase 2b Study of Bryostatin for Treatment of Severe
Alzheimers Disease 38
Feb 03, 2016: Neurotrope Holds Investigators Meeting for U.S. Phase 2b Trial of Bryostatin-1 for
Treatment of Alzheimers Disease 39
Jan 07, 2016: Neurotrope Initiates Phase 2b Study of Bryostatin for Treatment of Alzheimers Disease 39
Jul 20, 2015: Neurotrope to Showcase Bryostatin as a Potential Treatment for Alzheimer's Disease at the
2015 Alzheimer's Association International Conference 40
Jun 24, 2015: Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric
Disease 40
Request for Free Sample Report
Jun 12, 2015: Neurotrope to Present Findings of In-vitro Studies of Bryostatin's Effects on Niemann Pick
Type C1 Cells at the Annual "Michael, Marcia & Christa Parseghian Scientific Conference" for NiemannPick Type C 41
Apr 16, 2015: Neurotrope Receives Research Grant From the FRAXA Research Foundation to Fund PreClinical Fragile X Syndrome Behavioral Studies 42
Apr 09, 2015: Neurotrope Receives FDA Orphan Drug Designation for Bryostatin in the Treatment of
Fragile X Syndrome 42